Cytek Biosciences Expects Its FY23 Revenue To Be Near The High End Of The Co's Most Recent Revenue Guidance Range Of $188M-1$192M
Portfolio Pulse from Benzinga Newsdesk
Cytek Biosciences, Inc. (NASDAQ:CTKB) announced preliminary, unaudited FY23 revenue results, expecting to be near the high end of its $188M-$192M guidance range. The results are subject to year-end closing and audit adjustments. Cytek will provide finalized Q4 and FY23 results and 2024 guidance in an earnings call by end of February 2024. The announcement comes ahead of CEO Wenbin Jiang's presentation at the J.P. Morgan Healthcare Conference.
January 08, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cytek Biosciences expects FY23 revenue to be near the high end of its $188M-$192M guidance. Final results pending audit, with full report and 2024 guidance due in February.
Positive revenue guidance typically leads to increased investor confidence and can result in a short-term stock price increase. However, the final audited results are pending, which introduces some uncertainty. The upcoming earnings call and 2024 guidance will provide further clarity and could have additional impact on the stock price.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100